Karly Mather

Company: AstraZeneca

Job title: Senior Scientist

Seminars:

Beyond Incretins: Exploring the Quality of Weight Loss with AZD6234, a Novel Selective Amylin Receptor Agonist, and GLP-1RA Combinations in DIO Rats 8:00 am - 9:00 am

AZD6234 is a long-acting, selective amylin receptor agonist that mediates dose-dependent decreases in food intake and body weight change in obese rats Switching to AZD6234 after GLP1RA prevents body weight rebound and increases weight loss when combined with GLP1RA in obese rats AZD6234 promotes fat mass loss while preserving lean mass without compromising tolerability in pre-clinical…Read more

day: Day One